Biogen (BIIB) Competitors

Biogen (NASDAQ:BIIB) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, community ranking, dividends and analyst recommendations.

Which has more volatility & risk, BIIB or REGN?

Biogen has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500.

Is BIIB or REGN more profitable?

Regeneron Pharmaceuticals has a net margin of 31.07% compared to Biogen's net margin of 16.87%. Regeneron Pharmaceuticals' return on equity of 16.32% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	16.87%	14.98%	8.76%
Regeneron Pharmaceuticals	31.07%	16.32%	12.76%

Do analysts recommend BIIB or REGN?

Biogen currently has a consensus price target of $213.33, indicating a potential upside of 49.78%. Regeneron Pharmaceuticals has a consensus price target of $973.13, indicating a potential upside of 52.02%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	0 Sell rating(s)	17 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.43
Regeneron Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.76

Which has better earnings & valuation, BIIB or REGN?

Regeneron Pharmaceuticals has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.68B	2.15	$1.63B	$11.19	12.73
Regeneron Pharmaceuticals	$14.20B	4.93	$4.41B	$38.28	16.72

Do institutionals and insiders believe in BIIB or REGN?

87.9% of Biogen shares are held by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. 0.2% of Biogen shares are held by company insiders. Comparatively, 7.5% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Does the media prefer BIIB or REGN?

In the previous week, Regeneron Pharmaceuticals had 11 more articles in the media than Biogen. MarketBeat recorded 39 mentions for Regeneron Pharmaceuticals and 28 mentions for Biogen. Regeneron Pharmaceuticals' average media sentiment score of 1.40 beat Biogen's score of 1.17 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	21 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	31 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer BIIB or REGN?

Biogen received 268 more outperform votes than Regeneron Pharmaceuticals when rated by MarketBeat users. Likewise, 71.47% of users gave Biogen an outperform vote while only 66.93% of users gave Regeneron Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Biogen	Outperform Votes 1816 71.47%	Underperform Votes 725 28.53%
Regeneron Pharmaceuticals	Outperform Votes 1548 66.93%	Underperform Votes 765 33.07%

Summary

Regeneron Pharmaceuticals beats Biogen on 16 of the 19 factors compared between the two stocks.